Cargando…

MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients

BACKGROUND: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. DESIGN AND METHODS: We analyzed eight miR-SNPs by allelic discrimination in 141 p...

Descripción completa

Detalles Bibliográficos
Autores principales: Navarro, Alfons, Muñoz, Carmen, Gaya, Anna, Díaz-Beyá, Marina, Gel, Bernat, Tejero, Rut, Díaz, Tania, Martinez, Antonio, Monzó, Mariano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660374/
https://www.ncbi.nlm.nih.gov/pubmed/23705004
http://dx.doi.org/10.1371/journal.pone.0064716
_version_ 1782270555520499712
author Navarro, Alfons
Muñoz, Carmen
Gaya, Anna
Díaz-Beyá, Marina
Gel, Bernat
Tejero, Rut
Díaz, Tania
Martinez, Antonio
Monzó, Mariano
author_facet Navarro, Alfons
Muñoz, Carmen
Gaya, Anna
Díaz-Beyá, Marina
Gel, Bernat
Tejero, Rut
Díaz, Tania
Martinez, Antonio
Monzó, Mariano
author_sort Navarro, Alfons
collection PubMed
description BACKGROUND: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. DESIGN AND METHODS: We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS). RESULTS: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P = 0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P = 0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P = 0.036). XPO5 (P = 0.039) and TRBP (rs784567) (P = 0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P = 0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039–6.620; P = 0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P = 0.008) and OS (P = 0.008). CONCLUSION: miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse.
format Online
Article
Text
id pubmed-3660374
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-36603742013-05-23 MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients Navarro, Alfons Muñoz, Carmen Gaya, Anna Díaz-Beyá, Marina Gel, Bernat Tejero, Rut Díaz, Tania Martinez, Antonio Monzó, Mariano PLoS One Research Article BACKGROUND: In recent years, microRNA (miRNA) pathways have emerged as a crucial system for the regulation of tumorogenesis. miR-SNPs are a novel class of single nucleotide polymorphisms that can affect miRNA pathways. DESIGN AND METHODS: We analyzed eight miR-SNPs by allelic discrimination in 141 patients with Hodgkin lymphoma and correlated the results with treatment-related toxicity, response, disease-free survival (DFS) and overall survival (OS). RESULTS: The KRT81 (rs3660) GG genotype was associated with an increased risk of neurological toxicity (P = 0.016), while patients with XPO5 (rs11077) AA or CC genotypes had a higher rate of bleomycin-associated pulmonary toxicity (P = 0.048). Both miR-SNPs emerged as independent factors in the multivariate analysis. The XPO5 AA and CC genotypes were also associated with a lower response rate (P = 0.036). XPO5 (P = 0.039) and TRBP (rs784567) (P = 0.022) genotypes emerged as prognostic markers for DFS, and XPO5 was also associated with OS (P = 0.033). In the multivariate analysis, only XPO5 emerged as an independent prognostic factor for DFS (HR: 2.622; 95%CI 1.039–6.620; P = 0.041). Given the influence of XPO5 and TRBP as individual markers, we then investigated the combined effect of these miR-SNPs. Patients with both the XPO5 AA/CC and TRBP TT/TC genotypes had the shortest DFS (P = 0.008) and OS (P = 0.008). CONCLUSION: miR-SNPs can add useful prognostic information on treatment-related toxicity and clinical outcome in Hodgkin lymphoma and can be used to identify patients likely to be chemoresistant or to relapse. Public Library of Science 2013-05-21 /pmc/articles/PMC3660374/ /pubmed/23705004 http://dx.doi.org/10.1371/journal.pone.0064716 Text en © 2013 Navarro et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Navarro, Alfons
Muñoz, Carmen
Gaya, Anna
Díaz-Beyá, Marina
Gel, Bernat
Tejero, Rut
Díaz, Tania
Martinez, Antonio
Monzó, Mariano
MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
title MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
title_full MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
title_fullStr MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
title_full_unstemmed MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
title_short MiR-SNPs as Markers of Toxicity and Clinical Outcome in Hodgkin Lymphoma Patients
title_sort mir-snps as markers of toxicity and clinical outcome in hodgkin lymphoma patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3660374/
https://www.ncbi.nlm.nih.gov/pubmed/23705004
http://dx.doi.org/10.1371/journal.pone.0064716
work_keys_str_mv AT navarroalfons mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT munozcarmen mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT gayaanna mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT diazbeyamarina mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT gelbernat mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT tejerorut mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT diaztania mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT martinezantonio mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients
AT monzomariano mirsnpsasmarkersoftoxicityandclinicaloutcomeinhodgkinlymphomapatients